FDA's Division of Neurology Products continued its hot streak in 2017 with the approval of Teva Pharmaceutical Industries Ltd.'s Austedo (deutetrabenazine), the fourth novel agent to clear the division this year.
Austedo brings the novel approvals count from the Center for Drug Evaluation and Research (CDER) to 13 in 2017. The four neurology approvals – Austedo for Huntington's chorea, Ocrevus for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?